Skip to content

Study · Systematic review · 2015

4 results

Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis.

Mearns ES, Saulsberry WJ, White CM, Kohn CG, Lemieux S, Sihabout A, Salamucha I, Coleman CI

Diabetic medicine : a journal of the British Diabetic Association17 Jul 2015Cited by 38 (Europe PMC)

PMID26104021 (opens in a new tab)DOI10.1111/dme.12837 (opens in a new tab)PepBankPUB-26104021
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes failing metformin and sulphonylurea, adding liraglutide reduced HbA1c by 13 mmol/mol (1.20%) compared with placebo/control, the largest reduction of the agents.

    In plain wordsIn adults with type 2 diabetes, adding liraglutide lowered HbA1c more than placebo or control, the largest drop among the drugs compared.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction
    Study

    n: not reported in source

    Comparator
    Placebo/control
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c reduction
    13 mmol/mol
    liraglutide
    HbA1c reduction
    1.2%
    liraglutide

    Source sentences

    Summary
    Compared with placebo/control, all antihyperglycaemic agents reduced HbA1c levels, albeit by differing magnitudes [range 7 mmol/mol (0.6%) for acarbose to 13 mmol/mol (1.20%) for liraglutide].
    1 context sentence
    Summary · context
    Randomized trials evaluating antihyperglycaemic agents in adults with Type 2 diabetes experiencing poor glycaemic control despite optimized metformin and sulphonylurea therapy (≥ 1500 mg metformin or maximum tolerated dose; ≥ 50% of maximum sulphonylurea dose for ≥ 3 weeks) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes failing metformin and sulphonylurea, liraglutide decreased systolic blood pressure compared with placebo/control, pioglitazone, glargine and sitagliptin.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered systolic blood pressure compared with placebo, pioglitazone, glargine and sitagliptin.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Comparator
    Placebo/control, pioglitazone, glargine and sitagliptin
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Sodium glucose cotransporter-2 inhibitors, rosiglitazone and liraglutide decreased systolic blood pressure compared with placebo/control, pioglitazone, glargine and sitagliptin (2.41-8.88 mm Hg).
    1 context sentence
    Summary · context
    Randomized trials evaluating antihyperglycaemic agents in adults with Type 2 diabetes experiencing poor glycaemic control despite optimized metformin and sulphonylurea therapy (≥ 1500 mg metformin or maximum tolerated dose; ≥ 50% of maximum sulphonylurea dose for ≥ 3 weeks) were included.
  3. 03HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes failing metformin and sulphonylurea, liraglutide increased hypoglycaemia risk compared with placebo/control.

    In plain wordsIn adults with type 2 diabetes on metformin and a sulphonylurea, adding liraglutide raised the risk of low blood sugar compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseHypoglycaemia risk
    Study

    n: not reported in source

    Comparator
    Placebo/control
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Glargine, thiazolidinediones, liraglutide, sitagliptin and canagliflozin increased hypoglycaemia risk compared with placebo/control (relative risk 1.92-7.47), while glargine and rosiglitazone increased hypoglycaemia compared with most antihyperglycaemic agents (relative risk 2.81-7.47).
    1 context sentence
    Summary · context
    Randomized trials evaluating antihyperglycaemic agents in adults with Type 2 diabetes experiencing poor glycaemic control despite optimized metformin and sulphonylurea therapy (≥ 1500 mg metformin or maximum tolerated dose; ≥ 50% of maximum sulphonylurea dose for ≥ 3 weeks) were included.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with type 2 diabetes failing metformin and sulphonylurea, no antihyperglycaemic agent in the network, liraglutide included, increased the risk of urinary tract infection.

    In plain wordsIn adults with type 2 diabetes, none of the added drugs compared, liraglutide included, raised the risk of urinary tract infection.

    Peptide
    Liraglutide
    Outcome
    No significant changeUrinary tract infection risk
    Study

    n: not reported in source

    Comparator
    Placebo/control
    Outcome group
    Adverse events · Kidney and urinary

    Source sentences

    Summary
    No antihyperglycaemic agent increased the risk of urinary tract infection, but canagliflozin increased the risk of genital tract infection by 3.9-fold compared with placebo/control.
    1 context sentence
    Summary · context
    Randomized trials evaluating antihyperglycaemic agents in adults with Type 2 diabetes experiencing poor glycaemic control despite optimized metformin and sulphonylurea therapy (≥ 1500 mg metformin or maximum tolerated dose; ≥ 50% of maximum sulphonylurea dose for ≥ 3 weeks) were included.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.